RT Journal Article
SR Electronic
T1 COVID-19 vaccination coverage by company size and the effects of socioeconomic factors and workplace vaccination in Japan: a cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.30.22273203
DO 10.1101/2022.03.30.22273203
A1 Mori, Koji
A1 Mori, Takahiro
A1 Nagata, Tomohisa
A1 Ando, Hajime
A1 Hino, Ayako
A1 Tateishi, Seiichiro
A1 Tsuji, Mayumi
A1 Muramatsu, Keiji
A1 Fujino, Yoshihisa
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/04/06/2022.03.30.22273203.abstract
AB Background Vaccination is considered the most effective control measure against COVID-19. Vaccine hesitancy and equitable vaccine allocation are important challenges to disseminating developed vaccines. To promote COVID-19 vaccination coverage, the government of Japan established the workplace vaccination program. However, while it appears that the program was effective in overcoming vaccine hesitancy, the program may have hindered the equitable allocation of vaccines because it mainly focused on employees of large companies. We investigated the relationship between company size and COVID-19 vaccination completion status of employees and the impact of the workplace vaccination program on this relationship.Methods We conducted an internet-based prospective cohort study from December 2020 (baseline) to December 2021. The data were collected using a self-administered questionnaire survey. Briefly, 27,036 workers completed the questionnaire at baseline and 18,560 at follow-up. After excluding ineligible respondents, we finally analyzed the data from 15,829 participants. At baseline, the participants were asked about the size of the company they worked for, and at follow-up they were asked about the month in which they received their second COVID-19 vaccine dose and the availability of a company-arranged vaccination opportunity.Results In each month throughout the observation period, the odds of having received a second COVID-19 vaccine dose were significantly lower for small-company employees than for large-company employees in the sex- and age-adjusted model. This difference decreased after adjusting for socioeconomic factors, and there was no significant difference after adjusting for the availability of a company-arranged vaccination opportunity.Conclusions The workplace vaccination program implemented in Japan to control the COVID-19 pandemic may have been effective in overcoming vaccine hesitancy in workers; however, it may have caused an inequitable allocation of vaccines between companies of different sizes. Because people who worked for small companies were less likely to be vaccinated, it will be necessary to enhance support of vaccination for this population in the event of future infectious disease outbreaks.Trial registration Not applicable.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported and partly funded by research grants from the University of Occupational and Environmental Health, Japan (no grant number), the Japanese Ministry of Health, Labour and Welfare (H30-josei-ippan-002, H30-roudou-ippan-007, 19JA1004, 20JA1006, 210301-1, and 20HB1004), Anshin Zaidan (no grant number), the Collabo-Health Study Group (no grant number), Hitachi Systems, Ltd. (no grant number), and scholarship donations from Chugai Pharmaceutical Co., Ltd. (no grant number). The funders were not involved in the study design, collection, analysis, or interpretation of data, the writing of this article, or the decision to submit it for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethics committee of the University of Occupational and Environmental Health, Japan (reference nos. R2-079 and R3-006). Informed consent was obtained from all participants via the survey website.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsCOVID-19coronavirus diseases 2019mRNAmessenger RNAWHOWorld Health OrganizationJPNJapanese yenORodds ratioCIconfidence interval.